se of Montelucast in reducing the recurrence of steroid dependence nephrotic syndrome

Phase 2

Recruiting

• Conditions: frequently relapsing nephrotic syndrome with sensitivity to steroid.; Nephrotic syndrome with minor glomerular abnormality; N04.0

• Registration Number: IRCT20111024007892N9
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Patients with frequently relapsing nephrotic syndrome ( 4 times or more in a year)
sensitivity to steroid ( proper response to treatment with oral Corticosteroid with dosage of 1-2 mg/kg in a patient)

Exclusion Criteria

extreme edema
resistance to treatment with Corticosteroid

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ratio of urine protein to creatinine. Timepoint: before and one month after the beginning of treatment. Method of measurement: biochemical test.;Serum Albumin. Timepoint: before and one month after the beginning of treatment. Method of measurement: biochemical test.;Creatinine. Timepoint: before and one month after the beginning of treatment. Method of measurement: biochemical test.;Cholesterol. Timepoint: before and one month after the beginning of treatment. Method of measurement: investigation in laboratory.;Short term rate of recovery. Timepoint: one month after the beginning of treatment. Method of measurement: clinical observation.;Complications. Timepoint: one month after the beginning of treatment. Method of measurement: clinical observation.